BioMarin, Sarah Cannon Research UK Expand PARP Inhibitor Trial Outside US | GenomeWeb

NEW YORK (GenomeWeb) – Sarah Cannon Research UK is enrolling patients for BioMarin's Phase III EMBARCA trial investigating BMN 673 as a treatment for BRCA-mutation positive hereditary breast cancer.

In a statement, Sarah Cannon Research UK said it had enrolled the first patient in the EMBARCA study outside of the US, "expanding the trial internationally." The aim of the Phase III study is to evaluate the safety and efficacy of the PARP inhibitor BMN 673.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.